Intravitreal Bevacizumab for the Treatment of Neovascular Membranes in Patients With Intraocular Inflammation

Asociación para Evitar la Ceguera en México1 site in 1 countryDecember 2006

ConditionsVogt Koyanagi Harada Disease Serpiginous Choroiditis Multifocal Choroiditis

DrugsBevacizumab

Overview

Phase: Phase 3
Intervention: Not specified
Conditions: Vogt Koyanagi Harada Disease
Sponsor: Asociación para Evitar la Ceguera en México
Locations: 1
Primary Endpoint: Best corrected visual acuity
Status: Withdrawn
Last Updated: last year

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

Intravitreal injection of Bevacizumab in patients with Neovascular Membranes secondary to intraocular inflammation. We injected a single injection of Bevacizumab (2.5 mg/0.1 ml) and evaluate visual acuity , Fluorescein angiogram and retinal thickness by Optical Coherence Tomography (OCT) in 4 patients with Vogt Koyanagi Harada disease, 1 patient with Serpiginous Choroidopathy and 1 patient with Multifocal Choroiditis.

Registry

clinicaltrials.gov

Start Date

December 2006

End Date

December 2006

Last Updated

last year

Study Type

Interventional

Study Design

Single Group